Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study
Jung Sun Kim, Youngun Kim, Beodeul KANG, Il Hwan Kim, Hyeyeong Kim, Won Suk Lee, Jung Yong Hong, Ho Yeong Lim, Han Sang Kim, Chang Gon Kim, Chang Gon Kim, Sanghoon Jung, Chansik An, Chan Kim, Chan Kim, Hong Jae Chon
Cancer Medicine
초록
Nivo/Ipi combination therapy induced superior intrahepatic responses compared to Nivo monotherapy in patients with advanced HCC without prior ICI exposure, highlighting its potential to overcome liver-specific immune tolerance.